Local Regulatory Experts
Connect with regulatory affairs consultancies specializing in this region.
Qualtech Consulting Corporation
Taiwan, China, Japan, Singapore, Hong Kong, Malaysia, Philippines, Vietnam, Australia, Germany, Korea, Thailand, USA
A specialized medical device consulting firm offering a one-stop solution for complex global regulatory challenges. We offer real-time regulatory and clinical support, local representation, and QMS services across 13 markets, ensuring efficient market entry and compliance.
Cobridge Co., Ltd.
Tokyo, Japan
We assist medical device companies with the medical device registration and approval in Japan. Regulatory consulting services and DMAH services for foreign manufacturers to enter Japanese market.
MDREX, Medical Device, Digital Health Consulting Group
Seoul, Republic of Korea (HQ), Japan Office
We offer total solutions for market entry in South Korea and global expansion (e.g., Japan, USA, Europe). Key areas include product approval, reimbursement listings (HIRA), and Quality System certification (KGMP). They are particularly strong in innovative products like SaMD, medical wearables, and 3D printing for medical use, and provide in-depth expertise in cybersecurity and clinical trial planning.
CMIC Holdings Co., Ltd.
Tokyo, Japan (HQ), Osaka, Japan, Beijing, China, Seoul, South Korea, Taipei, Taiwan, Singapore, New York, USA, London, UK, Frankfurt, Germany, Sydney, Australia
We operate globally, specializing in accelerating the development, manufacturing, and commercialization of drugs and medical devices. Their expertise spans Phase I to IV clinical trials, regulatory affairs, quality assurance, and manufacturing, with a strong focus on the Japanese and Asian markets. Key services include clinical operations (CRO), manufacturing (CDMO/CMO), site management (SMO), and comprehensive health analysis and solutions.
January 1, 2026
Approximately 5 minutes
Consideration in the development of drugs for pulmonary arterial hypertension in Japan
Consideration in the Development of Drugs for Pulmonary Arterial Hypertension in Japan
1. Background and Purpose
Pulmonary arterial hypertension (PAH) is a serious, progressive vascular disease that leads to increased pulmonary arterial pressure and vascular resistance, potentially resulting in right heart failure and death. In Japan, PAH is designated as an intractable disease, with thousands of patients requiring targeted therapeutic options. Although several treatments with different mechanisms and routes of administration have been approved, unmet medical needs remain for patients whose prognosis is not sufficiently improved by existing therapies. To aid planning of future PAH drug development, the PMDA issued an Early Consideration document outlining key clinical development considerations. ([turn0view0]
2. Strategic Clinical Development Considerations
2.1 Multi-regional vs. Domestic Trials
Because PAH is a rare disease, conducting confirmatory trials in Japan alone with morbidity/mortality (M/M) events as primary endpoints is challenging. Therefore, early participation in multi-regional clinical trials (MRCTs) is recommended to strengthen the evidence package. If overseas confirmatory trials exist, sponsors may conduct comparative trials to evaluate efficacy and safety between Japanese and non-Japanese populations, aligning trial designs closely with referenced overseas studies where possible. ([turn0view0]
2.2 Primary Endpoints
The most scientifically rigorous primary endpoint for PAH confirmatory trials is a composite of M/M events (including clinical worsening and death), defined clearly in the study protocol. When event-driven designs are not feasible, alternatives such as pulmonary vascular resistance (PVR) or 6-minute walk distance (6MWD) may be acceptable, though 6MWD has limitations related to variability and clinical relevance. The choice of endpoints should reflect the goal of improving prognosis. ([turn0view0]
2.3 Secondary / Exploratory Endpoints
Secondary endpoints can include hemodynamic parameters (e.g., mean pulmonary arterial pressure, PVR), functional measures (e.g., exercise tolerance, WHO functional class), and other exploratory outcomes like echocardiographic parameters. These should be prespecified and justified in the protocol. ([turn0view0]
3. Study Design and Patient Considerations
3.1 Control Groups and Comparators
Confirmatory trials should generally be randomized, double-blind, comparative studies. Use of placebo with background therapy is acceptable, or active comparators (approved PAH drugs) may be used when demonstrating superiority or non-inferiority to existing therapies. ([turn0view0]
3.2 Target Patient Population
Study populations should include patients across the spectrum of PAH severity where the investigational drug is intended to be used. When concomitant use of existing PAH therapies is allowed, measures must be taken to minimize confounding effects on efficacy evaluation, such as requiring stable doses before study entry. ([turn0view0]
4. Dosage, Administration, and Safety
Careful specification of dosage and administration strategies is essential to allow dose adjustment, such as titration or dose reduction. Trial designs should also address safety monitoring over adequate durations, as PAH drugs are typically used long-term. Generally, safety data for at least 52 weeks of administration is expected. ([turn0view0]
5. Pediatric Development
PAH also affects pediatric patients, and PMDA strongly recommends planning pediatric development in parallel with adult trials. Given the limited number of pediatric patients with PAH and the difficulty of standalone confirmatory trials, strategies may include leveraging adult trial data to support pediatric efficacy, with primary endpoints and study designs adapted according to age and weight categories. Consultation with PMDA on pediatric planning and trial design is advised. ([turn0view0]
6. Early Engagement with PMDA
Consistent with Early Consideration principles, the document underscores the importance of consulting PMDA early in development planning to discuss proposed trial designs, endpoints, and overall strategy to ensure alignment with regulatory expectations and reduce potential delays during review. ([turn0view0]
References
- PMDA Early Consideration: Consideration in the development of drugs for pulmonary arterial hypertension (Office of New Drug II, Jan 7, 2025), Provisional Translation. ([turn0view0]
Have a Question?
Ask our experts about this topic. We'll do our best to respond to your question.
Related Articles
Approximately 5 minutes
Points to Consider in Developing Drugs for Pediatric Inflammatory Bowel Disease in Japan
PMDA released points to consider for planning clinical studies in pediatric inflammatory bowel disease (IBD) drug development, aiming to improve availability of therapies for children by addressing pediatric-specific challenges.
Approximately 5 minutes
Points to Consider in the Clinical Development of Drugs for Transthyretin Amyloid Cardiomyopathy (Early Consideration) in Japan
This PMDA Early Consideration document outlines strategic clinical development points for transthyretin amyloid cardiomyopathy (ATTR-CM) drugs in Japan, including rare disease considerations, endpoint selection, trial design, and multi-regional development.
Approximately 5 minutes
Points to Consider for the Design of Clinical Trials to Assess the Effects of Psychotropic Drugs on Driving Performance in Japan
This PMDA Early Consideration outlines key considerations for designing clinical trials to assess impacts of psychotropic drugs on driving performance, focusing on clinically meaningful driving impairment and appropriate evaluation methods.
Approximately 5 minutes
Japan Specialty Fulfillment for Medical Devices: Low Volume, High Value Sales
Specialty Fulfillment is a crucial service for foreign medical device manufacturers targeting low-volume, high-value sales in Japan, often utilizing an Independent License Holder to manage customs, storage, and distribution to maintain high profit margins.
Approximately 5 minutes
Points to Consider for the Design of Clinical Trials to Assess the Effects of Psychotropic Drugs on Driving Performance in Japan
This PMDA Early Consideration outlines key considerations for designing clinical trials to assess impacts of psychotropic drugs on driving performance, focusing on clinically meaningful driving impairment and appropriate evaluation methods.
Approximately 5 minutes
Guideline for Clinical Evaluation of Antibacterial Drugs in Japan
The PMDA’s *Guideline for Clinical Evaluation of Antibacterial Drugs* provides comprehensive principles for designing and conducting clinical studies of antibacterial drugs for regulatory approval, reflecting current scientific knowledge and global harmonization.
Approximately 5 minutes
Considerations for Non-clinical Studies of Combination Prescription Drugs with Similar Formulations in Japan
PMDA’s Early Consideration document clarifies how non-clinical pharmacology and toxicology studies should be approached for combination prescription drugs whose formulations are similar to approved products.
Approximately 5 minutes
Points to Consider for Clinical Development of Drugs Intended for Treatment of Psoriatic Arthritis in Japan
This PMDA Early Consideration outlines current regulatory thinking for clinical development of psoriatic arthritis (PsA) drugs in Japan, including disease characterization, endpoints, study design considerations, and use of global data.
Approximately 5 minutes
On Release of the Guideline for Clinical Evaluation of Oral Hypoglycemic Agents in Japan
The *Guideline for Clinical Evaluation of Oral Hypoglycemic Agents* provides comprehensive procedures for planning, conducting, and evaluating clinical studies of oral hypoglycemic agents in Japan, focusing on glycemic control markers, safety evaluation, and inclusion of relevant patient populations.
Approximately 5 minutes
Considerations for Non-Clinical Studies in the Development of Diagnostic Radiopharmaceuticals in Japan
PMDA’s Early Consideration (Mar 26, 2025) explains when non-clinical packages for diagnostic radiopharmaceuticals can be streamlined (e.g., microdose), and how to address safety pharmacology, DDI/ADME, toxicity, and radiolytic impurities.
Approximately 5 minutes
Guideline for Clinical Evaluation of Diagnostic Radiopharmaceuticals in Japan
PMDA/MHLW’s guideline (PFSB/ELD Notification No. 0611-1) explains how to design non-clinical and clinical evidence for diagnostic radiopharmaceutical approval in Japan, emphasizing imaging accuracy, clinical significance, and radiation dosimetry.
Approximately 5 minutes
Checklist for Japan’s 30-day Clinical Trial Notification Review (Initial CTN, Oncology Drugs)
PMDA’s early-consideration checklist summarizes what reviewers expect to see in an initial CTN for oncology drugs—covering safety reporting workflows, Phase 1 population ethics, starting dose rationale, DLT/tolerability evaluation, informed consent essentials, and required attached documents.
Approximately 5 minutes
Statistical Considerations for Phase I Oncology Trials in Japan (Safety-focused Early Consideration)
PMDA’s early-consideration paper explains what statistical evidence and simulation outputs should support oncology Phase I dose-escalation designs in Japan’s 30-day CTN review, with emphasis on safety, termination behavior under excessive toxicity, and managing design modifications like backfilling or schedule changes.